<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cystic fibrosis: Management of pulmonary exacerbations</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cystic fibrosis: Management of pulmonary exacerbations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cystic fibrosis: Management of pulmonary exacerbations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Simon, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Chmiel, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4119162004"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cystic fibrosis (CF) is a multisystem disorder caused by pathogenic variants in the <em>CFTR</em> gene (CF transmembrane conductance regulator) [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/6368.html" rel="external">"Cystic fibrosis: Genetics and pathogenesis"</a>.)</p><p>Pulmonary disease remains the leading cause of morbidity and mortality in people with CF [<a href="#rid3">3</a>], and pulmonary exacerbations are associated with accelerated loss of lung function, decreased quality of life, and increased mortality [<a href="#rid4">4-7</a>]. The causes of pulmonary exacerbations are multifactorial, with infection playing an important but somewhat ill-defined role [<a href="#rid8">8</a>]. The development of treatments that reduce the frequency and severity of pulmonary exacerbations is an important contributor to the marked improvements in survival of people with CF  (<a class="graphic graphic_figure graphicRef61930" href="/d/graphic/61930.html" rel="external">figure 1</a>).</p><p>Considerable variation exists in how patients with CF are treated for pulmonary exacerbations [<a href="#rid9">9-12</a>], despite the availability of clinical guidelines [<a href="#rid13">13-16</a>]. The recommendations in this topic review generally adhere to published guidelines and/or conform to common clinical practices.</p><p>Treatment of pulmonary exacerbations in CF is multifaceted, involving antibiotics, chest physiotherapy, inhaled medications to promote secretion clearance, and, sometimes, antiinflammatory agents. An overview of these interventions will be reviewed here. Selection of antibiotics for pulmonary exacerbations is discussed in a separate topic review. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.)</p><p>Other aspects of pulmonary disease in CF are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6369.html" rel="external">"Cystic fibrosis: Clinical manifestations of pulmonary disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease"</a>.)</p><p></p><p class="headingAnchor" id="H3265945185"><span class="h1">PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS</span></p><p class="headingAnchor" id="H3781362999"><span class="h2">Definition</span><span class="headingEndMark"> — </span>The clinical course of most patients with CF is punctuated by acute episodes of worsening pulmonary status that are referred to as "pulmonary exacerbations" [<a href="#rid17">17,18</a>]. The CF field has not reached a consensus definition of pulmonary exacerbation for the purposes of patient care or clinical research [<a href="#rid19">19,20</a>]. In many clinical trials, exacerbations were defined solely on the criterion that a participant's CF clinician initiated antibiotic treatment for an acute worsening of clinical status [<a href="#rid10">10,21</a>]. Other trials have defined exacerbations based on specific symptoms and signs, but these criteria do not perform well at identifying those patients whose CF clinicians choose to treat with antibiotics [<a href="#rid19">19,20</a>]. Part of the difficulty may be that pulmonary exacerbations are not a single entity but have differing etiologies, inflammatory profiles, and clinical outcomes [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H4222989483"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>In clinical practice, a pulmonary exacerbation is diagnosed based on <strong>changes</strong> from an individual patient's recent baseline health status [<a href="#rid24">24</a>], typically including several of the following symptoms and signs:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New or increased cough</p><p class="bulletIndent2"><span class="glyph">•</span>New or increased sputum production or chest congestion</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased exercise tolerance or new or increased dyspnea with exertion or at rest</p><p class="bulletIndent2"><span class="glyph">•</span>Increased fatigue</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased appetite and possible weight loss</p><p class="bulletIndent2"><span class="glyph">•</span>Increased respiratory rate at rest</p><p class="bulletIndent2"><span class="glyph">•</span>Change in sputum appearance</p><p class="bulletIndent2"><span class="glyph">•</span>Hemoptysis</p><p class="bulletIndent2"><span class="glyph">•</span>Fever (present in a minority of patients)</p><p class="bulletIndent2"><span class="glyph">•</span>Increased nasal congestion or drainage</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary function tests</strong> – Reductions in pulmonary function as measured by forced expiratory volume in one second (FEV<sub>1</sub>) are often present during pulmonary exacerbations but are not required for its diagnosis, although large decrements in FEV<sub>1</sub> (eg, more than a 10 percent decline from baseline) are more likely to cause clinicians to initiate treatment in patients presenting with typical signs and symptoms of an exacerbation [<a href="#rid25">25</a>]. Although it was hypothesized that routine monitoring by home spirometry would promote earlier detection of pulmonary exacerbations and therefore better outcomes, a randomized 52-week study in which people with CF were monitored twice weekly with home spirometry failed to detect long-term benefit relative to usual management, as measured by rate of decline of FEV<sub>1</sub> [<a href="#rid26">26</a>]. Contrasting results were found in a report from another CF center that instituted a new protocol in which a drop in FEV<sub>1</sub> (≥5 points from baseline) triggered treatment for a pulmonary exacerbation and reported subsequent improvement in mean FEV<sub>1</sub> across the center's patient population [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Chest radiographs may not show significant changes over baseline and are not routinely obtained for people with mild symptoms. A decrease in arterial hemoglobin oxygen saturation may occur but is not required to diagnose an exacerbation.</p><p></p><p>There are no absolute thresholds that determine a pulmonary exacerbation. For example, an individual who is asymptomatic at baseline is typically considered to have a pulmonary exacerbation if there is a new cough with sputum production, fatigue, and decreased appetite, even though FEV<sub>1</sub> may remain in normal range [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H2553181144"><span class="h2">Severity grading</span><span class="headingEndMark"> — </span>CF clinicians routinely distinguish mild from severe exacerbations when planning treatment [<a href="#rid9">9,29</a>], although there are no protocols for severity grading [<a href="#rid30">30</a>]. A common approach is to consider the degree of worsening from baseline of each of the patient's signs and symptoms and arrive at a global assessment of the extent of decline. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In an individual with mild pulmonary disease at baseline, an exacerbation is considered severe if the acute illness is characterized by the onset of a productive cough and a large decline in FEV<sub>1</sub> (eg, greater than 10 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an individual with severe pulmonary disease at baseline, an exacerbation is considered mild if the cough, sputum production, exercise tolerance, and FEV<sub>1</sub> worsened minimally but perceptibly from prior baseline status.</p><p></p><p class="headingAnchor" id="H2177996686"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>In 2022, the Cystic Fibrosis Foundation Patient Registry reported that 10 percent of children and 15 percent of adults had at least one pulmonary exacerbation severe enough to be treated with intravenous antibiotics, down from 23 percent of children and 43 percent of adults in 2018 [<a href="#rid3">3</a>]. A major driver of the decreased incidence is the availability of the highly effective CF transmembrane conductance regulator (CFTR) modulator <a class="drug drug_general" data-topicid="122968" href="/d/drug information/122968.html" rel="external">elexacaftor-tezacaftor-ivacaftor</a>, which brings treatment to approximately 94 percent of patients ≥6 years of age (see  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>). The improvement was probably also related to changes in exposure to respiratory viruses during the coronavirus disease 2019 (COVID-19) pandemic due to social distancing and mask wearing [<a href="#rid31">31</a>].</p><p>The risk of pulmonary exacerbation increases with age, female sex, declining lung function, CF-related diabetes, and cirrhosis [<a href="#rid32">32</a>]. A strong predictor of developing a pulmonary exacerbation is having had one or more exacerbations during the previous year. Other risk factors include nonadherence to chronic CF treatments and depression [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H531923525"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H1404189791"><span class="h2">Viruses</span><span class="headingEndMark"> — </span>Viruses are detected in many cases of acute exacerbations in children with CF, and there is some evidence that they are important contributors to declining pulmonary function. Among children with a pulmonary exacerbation during the winter months, viruses were detected by a molecular method in 34 to 60 percent [<a href="#rid35">35,36</a>]. The pathogens were coxsackie/echovirus, rhinovirus/enterovirus, respiratory syncytial virus, parainfluenza, adenovirus, and influenza. Among adults with pulmonary exacerbations, viruses were detected in 10 to 25 percent, especially rhinovirus, enterovirus, respiratory syncytial virus, parainfluenza virus, coronaviruses, and influenza [<a href="#rid37">37-39</a>].</p><p class="headingAnchor" id="H2211455913"><span class="h2">Bacteria</span><span class="headingEndMark"> — </span>Most people with CF have chronic bacterial infection of the airways, as demonstrated by sputum cultures; the prevalence of each bacterial type varies with the age of the patient  (<a class="graphic graphic_figure graphicRef74073" href="/d/graphic/74073.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Pathogens'</a>.)</p><p>Important pathogens include  (<a class="graphic graphic_table graphicRef55018" href="/d/graphic/55018.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><em>Pseudomonas</em> <em>aeruginosa</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>Staphylococcus</em> <em>aureus</em> (methicillin-sensitive or methicillin-resistant species)</p><p class="bulletIndent1"><span class="glyph">●</span><em>Burkholderia</em> <em>cepacia</em> complex</p><p class="bulletIndent1"><span class="glyph">●</span>Nontypeable <em>Haemophilus</em> <em>influenzae</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>Stenotrophomonas</em> <em>maltophilia</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>Achromobacter</em> species</p><p class="bulletIndent1"><span class="glyph">●</span>Nontuberculous mycobacteria</p><p></p><p>Anaerobic bacteria are frequently identified, but their role in pulmonary exacerbations is uncertain [<a href="#rid40">40-42</a>]. Nonculture-based assays to identify bacteria have shown that the number of species present in respiratory secretions from CF patients is often considerably higher than what is revealed by culture-based methods, with substantial variation among patients [<a href="#rid43">43</a>].</p><p>Although bacteria are clearly involved in the pathophysiology of pulmonary exacerbations in CF, the mechanisms are uncertain [<a href="#rid8">8,44</a>]. Most exacerbations are not associated with the appearance of new bacterial species or strains. Furthermore, there is no consistent pattern of change in bacterial communities leading up to pulmonary exacerbations [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3645828726"><span class="h2">Inflammation</span><span class="headingEndMark"> — </span>The CF airway is characterized by chronic neutrophil-rich inflammation (see  <a class="medical medical_review" href="/d/html/6369.html" rel="external">"Cystic fibrosis: Clinical manifestations of pulmonary disease"</a>). Inflammatory markers in serum and airway secretions increase during pulmonary exacerbations [<a href="#rid22">22,45,46</a>] and decrease with treatment [<a href="#rid47">47</a>]. Although pulmonary infection is a major contributor to the airway inflammation, there is some evidence that CF transmembrane conductance regulator (CFTR) deficiency itself can cause inflammation in the absence of infection [<a href="#rid48">48</a>]. During an exacerbation, bacterial or viral infection induces further inflammation, which contributes to the lung damage. As a result, some antiinflammatory strategies are effective at limiting lung damage. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Antiinflammatory therapy'</a>.)</p><p class="headingAnchor" id="H54600217"><span class="h1">SITE OF CARE</span><span class="headingEndMark"> — </span>Severe pulmonary exacerbations usually require hospitalization to adequately manage the complex regimen; closely monitor symptoms and laboratory test results; and ensure intensive airway clearance therapy, nutrition, and rest.</p><p class="headingAnchor" id="H466250473"><span class="h2">Home management of exacerbations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild exacerbations</strong> – Most mild exacerbations can be managed in an outpatient setting, using oral and/or inhaled antibiotics and intensified airway clearance therapies. Clinical care should include counseling to encourage close adherence to the regimen and close follow-up to monitor progress. Some patients with mild exacerbations will still require hospitalization and/or intravenous antibiotics, particularly if they show inadequate improvement or if they have failed outpatient oral/inhaled regimens during prior episodes. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Severity of the exacerbation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate exacerbations</strong> – Moderate or severe pulmonary exacerbations are often managed in an inpatient setting. However, home management may be appropriate for select patients with nonsevere exacerbations and sufficient support to ensure optimal treatment. When considering home therapy for a pulmonary exacerbation, resources must be available at home to replicate the hospital program, including the prescribed antibiotics and close adherence to airway clearance therapies (inhaled agents and chest physiotherapy), with provisions for rest and good nutrition [<a href="#rid13">13</a>]. Children require greater assistance than adults to accomplish these goals, and adult supervision is needed even for teenagers. In considering home treatment for children, one must consider the impact of lost work hours, the number of other children in the household, the number and competence of available adult caregivers, and family stress before deciding whether home treatment is preferable to hospitalization.</p><p></p><p class="bulletIndent1">Concern over hospital costs as well as the preference of many patients have encouraged home treatment with intravenous antibiotics for pulmonary exacerbations in CF. Although studies vary in their conclusions, a preponderance of evidence suggests that in-hospital treatment may be more effective. This was shown in a large prospective study of standardized care for pulmonary exacerbations (STOP2 study [<a href="#rid21">21</a>]), in which 33 percent of participants received treatment exclusively in hospital, 21 percent exclusively at home, and 46 percent initiated in hospital and completed at home [<a href="#rid49">49</a>]. The mean increase in percent predicted forced expiratory volume in one second (FEV<sub>1</sub>) of those treated only in hospital (8.0, 95% CI 6.7-9.4) was significantly better than those treated only at home (5.0, 95% CI 3.5-6.5) or at both locations (7.0, 95% CI 5.9-8.1). Because the participants were not randomly assigned to treatment location, sophisticated statistical analyses were used to adjust for assignment bias in these studies, but residual bias cannot be excluded. Similar conclusions were reached in another registry-based study of 4497 pulmonary exacerbations, which found that recovery of FEV<sub>1</sub> to ≥90 percent of baseline level was 9.1 percent more likely when all treatment was delivered in-hospital compared with treatment delivered entirely at home [<a href="#rid50">50</a>]. By contrast, some earlier and smaller studies detected no significant differences in outcomes for patients treated with intravenous antibiotics at home, including one very small randomized trial (31 exacerbations, 17 participants) [<a href="#rid51">51,52</a>] and an observational study (1535 participants) [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H4182211239"><span class="h2">Intensive care unit treatment</span><span class="headingEndMark"> — </span>Indications for intensive care unit (ICU) care include:</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory insufficiency requiring respiratory support (see <a class="local">'Respiratory support'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumothorax (see  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Spontaneous pneumothorax'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe hemoptysis (see  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Hemoptysis'</a>)</p><p></p><p>Outcomes for adults and children with CF who require ICU care were previously reported to be uniformly poor [<a href="#rid54">54</a>] but have fortunately improved [<a href="#rid55">55,56</a>]. Advanced CF lung disease should not be considered a contraindication to mechanical ventilation or ICU care in general, regardless of the patient's lung transplant status [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Intensive care unit treatment'</a>.)</p><p>An episode of respiratory failure should prompt discussion of end-of-life care, quality of life, and possible indications for lung transplantation. Ideally, these discussions should occur when a patient's clinical trajectory suggests increasing risk for respiratory failure but well before ICU care is needed. (See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Lung transplant evaluation'</a>.)</p><p class="headingAnchor" id="H2503543636"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The goals of treatment are to return the patient's symptoms to baseline and recover any lost forced expiratory volume in one second (FEV<sub>1</sub>), which are not always possible. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H2741282445"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>Treatment of exacerbations with systemic antibiotics is a mainstay of CF care and is recommended in virtually all consensus guidelines. Selection and dosing of antibiotics are summarized in the table  (<a class="graphic graphic_table graphicRef59661" href="/d/graphic/59661.html" rel="external">table 2</a>) and discussed separately. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.)</p><p>Periodic elective hospitalization for preventive therapy (referred to as "clean outs") is not recommended, as reviewed separately. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Periodic hospitalizations'</a>.)</p><p class="headingAnchor" id="H377902408"><span class="h2">Continuation of the chronic treatment regimen</span><span class="headingEndMark"> — </span>The patient's chronic treatment regimen should be continued or intensified during an acute exacerbation, as recommended by virtually all guidelines, although high-quality studies are generally lacking to assess this strategy [<a href="#rid13">13</a>]. The role for inhaled antibiotics during pulmonary exacerbations is uncertain. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Managing the chronically prescribed antibiotics'</a>.)</p><p>Key components include:</p><p class="bulletIndent1"><span class="glyph">●</span>CF transmembrane conductance regulator (CFTR) modulators. (See  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airway clearance therapy, with inhaled agents (eg, inhaled dornase alfa or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) and chest physiotherapy. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Airway clearance therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiinflammatory medications (eg, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>) in selected patients. Decisions about continuing or suspending azithromycin during a pulmonary exacerbation are discussed separately. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Managing the chronically prescribed antibiotics'</a> and  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Antiinflammatory therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimization of nutritional status. (See  <a class="medical medical_review" href="/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues", section on 'Nutrition support'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ensuring glucose control for those with CF-related diabetes. (See  <a class="medical medical_review" href="/d/html/14544.html" rel="external">"Cystic fibrosis-related diabetes mellitus", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise, as tolerated. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Chest physiotherapy'</a>.)</p><p></p><p>Many patients have poor adherence to these treatments when they are at their baseline status and require encouragement to increase their use during exacerbations [<a href="#rid33">33</a>]. If possible, the frequency of airway clearance treatments should be increased during exacerbations beyond what is prescribed as part of the chronic therapy regimen (eg, increasing to four times per day), as recommended by Cystic Fibrosis Foundation guidelines [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1277525515"><span class="h2">Other medications (for selected patients)</span></p><p class="headingAnchor" id="H658033937"><span class="h3">Bronchodilators</span><span class="headingEndMark"> — </span>During pulmonary exacerbations, our practice is to administer short-acting bronchodilator medications:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior to airway clearance therapy and exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Prior to other inhaled medications for those who develop bronchial constriction in response to them</p><p class="bulletIndent1"><span class="glyph">●</span>As a rescue medication for those with airway hyperreactivity</p><p></p><p>We use these same indications for bronchodilators during baseline health. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Bronchodilators'</a>.)</p><p>Evidence supporting routine use of bronchodilators during pulmonary exacerbations is limited. Poor responsiveness to bronchodilators was reported in a retrospective study in which the median bronchodilator-induced increase in FEV<sub>1</sub> was only 4.3 percent and only 9 percent of the participants met standard criteria for being responsive to bronchodilator treatment [<a href="#rid58">58</a>]. Somewhat better bronchodilator responsiveness was shown in a randomized crossover study that compared the effects of <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a> with placebo (normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) in 24 hospitalized patients who were evaluated after they had been on antibiotic therapy for at least six days [<a href="#rid59">59</a>]. A significant increase in FEV<sub>1</sub> was seen 45 minutes following albuterol administration but not following normal saline (mean FEV<sub>1</sub> increase 14.8 versus 1 percent). However, by the following morning, there was no between-group difference in FEV<sub>1</sub>. No studies have evaluated more prolonged effects of bronchodilators on pulmonary exacerbations, eg, duration of antibiotic treatment, recovery to baseline FEV<sub>1</sub>, or improvement in symptoms.</p><p class="headingAnchor" id="H100228217"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>There is considerable variation in practice regarding use of glucocorticoids for pulmonary exacerbations, and evidence is limited [<a href="#rid11">11,60</a>].</p><p>Our practice is to administer a course of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (2 mg/kg/day [maximum 60 mg daily] for five days) to the small subset of CF patients whose exacerbations have characteristics of an acute asthmatic episode (eg, chest tightness, wheezing, acute symptomatic response to inhaled beta-adrenergic agonists). We use this strategy because glucocorticoids are beneficial for asthmatic symptoms in patients without CF. (See  <a class="medical medical_review" href="/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Systemic glucocorticoids'</a> and  <a class="medical medical_review" href="/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management", section on 'Initiation of oral glucocorticoids'</a>.)</p><p>Other CF clinicians administer a brief course of glucocorticoids for all patients with exacerbations, regardless of the presence of asthma-like symptoms. This strategy is based on the assumption that acute exacerbations in CF are similar to acute exacerbations of chronic obstructive pulmonary disease (COPD) in adults (see  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>). However, we do not use this approach, because the few available studies suggest that systemic glucocorticoids do not improve pulmonary outcomes in people with CF and may contribute to dysglycemia [<a href="#rid61">61-63</a>].</p><p>Another strategy used by some clinicians is to administer systemic glucocorticoids to patients whose response to initial treatment is deemed suboptimal. Because of the scarcity of data evaluating glucocorticoids for pulmonary exacerbations, the Cystic Fibrosis Foundation did not make a recommendation regarding their use [<a href="#rid13">13</a>]. A clinical trial is underway that is evaluating the efficacy and safety of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> as adjunctive treatment for people with insufficient response to initial antibiotic treatment (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03070522&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQA4xV9rISjvUYOXwYGEWahYsbHu51GwPD4anQxVe9n2w%3D%3D&amp;TOPIC_ID=110933" target="_blank">NCT03070522</a>).</p><p class="headingAnchor" id="H1423607447"><span class="h3">Antiviral agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza</strong> – Antiviral treatment is indicated for people with CF with known or suspected influenza because they are at high risk for severe or complicated disease. Antiviral treatment should be initiated regardless of the duration of symptoms or severity of initial illness, although it is likely to have the greatest benefit if it is initiated within 48 hours after symptom onset. Indications and regimens are discussed separately. (See  <a class="medical medical_review" href="/d/html/5985.html" rel="external">"Seasonal influenza in children: Management", section on 'Antiviral therapy'</a> and  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1">Annual vaccination against viral influenza is recommended for all CF patients older than six months of age, using an inactivated vaccine delivered by injection. Vaccination is highly preferred over the use of pre- or postexposure chemoprophylaxis [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Prevention of infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19</strong> – CF is a condition associated with a higher risk of developing severe COVID-19 disease, according to the United States Centers for Disease Control and Prevention (CDC). Patients with CF should follow CDC recommendations for higher-risk individuals regarding vaccination and treatment of infection (see  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/d/html/128389.html" rel="external">"COVID-19: Management in children"</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>). Of note, <a class="drug drug_general" data-topicid="134695" href="/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a>, which is used to treat mild to moderate COVID-19 disease in adults, is a strong cytochrome P450 3A4 (CYP3A) inhibitor and will reduce the clearance of CFTR modulators. Administration of nirmatrelvir-ritonavir requires large reductions in modulator doses [<a href="#rid65">65</a>]; consultation with a pharmacist is advisable.</p><p></p><p class="headingAnchor" id="H676080280"><span class="h2">Respiratory support</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplemental oxygen</strong> – We administer supplemental oxygen as needed during pulmonary exacerbations, targeting an oxygen hemoglobin saturation by pulse oximetry of 88 to 92 percent or an arterial blood oxygen tension of 60 to 70 mmHg. This approach is based on the guidelines that are used for patients with acute exacerbations of COPD. No CF-specific clinical trials of supplemental oxygen administration have been performed that would modify these COPD recommendations. After initiation of supplemental oxygen, patients should be monitored for deterioration in mental status due to hypercapnia, although the incidence of this complication is low. (See  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninvasive ventilation</strong> – We offer noninvasive positive pressure ventilation to patients who develop acute respiratory failure (eg, acute elevation of arterial carbon dioxide tension to &gt;45 mmHg or hypercapnic acidosis) and who have none of the contraindications (eg, severely impaired consciousness, inability to cooperate, or inability to protect their airway). The noninvasive ventilation regimen must accommodate intermittent treatments for assisting airway secretion clearance (inhaled airway clearance medications and chest physiotherapy). The decisions are consistent with guidelines for people with COPD who develop acute ventilatory failure during exacerbations. (See  <a class="medical medical_review" href="/d/html/1636.html" rel="external">"Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"</a>.)</p><p></p><p class="bulletIndent1">The possibility that noninvasive ventilation might enhance airway clearance therapy was evaluated in a randomized study of 38 participants admitted for treatment of a pulmonary exacerbation [<a href="#rid66">66</a>]. There was no significant increased rate of improvement in FEV<sub>1</sub> or symptom scores in the noninvasive ventilation group [<a href="#rid66">66</a>]. Thus, we do not recommend noninvasive ventilation for the purposes of enhancing airway clearance therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive ventilation</strong> – CF patients with acute respiratory failure are candidates for endotracheal intubation and mechanical ventilation, if noninvasive ventilation fails and if the intervention is congruent with the patient's goals of care. The decisions are consistent with guidelines used for people with COPD and acute respiratory failure. (See  <a class="medical medical_review" href="/d/html/1632.html" rel="external">"Invasive mechanical ventilation in acute respiratory failure complicating chronic obstructive pulmonary disease"</a>.)</p><p></p><p class="bulletIndent1">Input from the appropriate transplant center should be sought to determine how intubation with mechanical ventilation will affect the patient's listing for transplantation. (See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracorporeal membrane oxygenation support (ECMO)</strong> – When adequate ventilation and/or oxygenation cannot be supported by assisted ventilation, ECMO has been used to successfully bridge CF patients to lung transplantation [<a href="#rid67">67,68</a>]. (See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Intensive care unit treatment'</a>.)</p><p></p><p class="bulletIndent1">Individuals who require invasive ventilation should also be considered for early institution of ECMO, if this is congruent with the patient's goals of care and with input from the pertinent transplant center, as outlined in Cystic Fibrosis Foundation guidelines for advanced CF lung disease [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/1625.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: Overview"</a>.)</p><p></p><p class="headingAnchor" id="H157816333"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Following a pulmonary exacerbation, recovery of the forced expiratory volume in one second (FEV<sub>1</sub>) decrement is often incomplete. With each exacerbation, between 12 and 35 percent of patients fail to recover to at least 90 percent of their baseline FEV<sub>1</sub> [<a href="#rid10">10,69,70</a>]. Quality of life also declines with increasing numbers of pulmonary exacerbations [<a href="#rid6">6</a>]. Following treatment of a pulmonary exacerbation, symptomatic improvements are not well correlated with FEV<sub>1</sub> recovery [<a href="#rid71">71</a>]. As an example, in a prospective study of 58 adults with CF, 23 percent of pulmonary exacerbations were associated with ongoing symptoms after 14 days of antibiotics, with further symptomatic improvement when treatment was extended to 21 days [<a href="#rid72">72</a>]. However, continuation of antibiotic treatment was not associated with further improvement in FEV<sub>1</sub> or body mass index. These observations are relevant to decisions about duration of treatment. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Duration of treatment'</a>.)</p><p>Given the adverse consequences of exacerbations, reducing exacerbation frequency is an important rationale for many of the chronic treatments for CF pulmonary disease. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease"</a> and  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a> and  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p class="headingAnchor" id="H2468150407"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109226.html" rel="external">"Society guideline links: Cystic fibrosis"</a>.)</p><p class="headingAnchor" id="H2650091467"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – In clinical practice, a pulmonary exacerbation is diagnosed based on a clinician's global assessment of changes from the patient's recent baseline health status, including changes in symptoms (cough, sputum production, exercise tolerance) with or without changes in pulmonary function tests. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The clinical course of cystic fibrosis (CF) is frequently complicated by acute pulmonary exacerbations, superimposed on a gradual decline in pulmonary function. Mechanisms include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacteria</strong> – Bacteria play an important but somewhat ill-defined role in the pathophysiology of pulmonary exacerbations. Key bacterial pathogens are discussed separately  (<a class="graphic graphic_table graphicRef55018" href="/d/graphic/55018.html" rel="external">table 1</a>). (See <a class="local">'Bacteria'</a> above and  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Pathogens'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Viruses</strong> – Viral pathogens frequently play a role in initiating exacerbations and may be important contributors to declining pulmonary function. Influenza is an important vaccine-preventable pathogen. (See <a class="local">'Viruses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotics</strong> – Treatment of exacerbations with systemic antibiotics is a mainstay of CF care. Selection and dosing of antibiotics are summarized in the table  (<a class="graphic graphic_table graphicRef59661" href="/d/graphic/59661.html" rel="external">table 2</a>) and discussed separately. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Continuation of the chronic treatment regimen</strong> – The patient's chronic treatment regimen should be continued or intensified during an acute exacerbation, including CF transmembrane modulator (CFTR) therapy, airway clearance therapies, optimization of nutrition, and management of CF-related diabetes (if present). (See <a class="local">'Continuation of the chronic treatment regimen'</a> above.)</p><p></p><p class="bulletIndent2">The role for inhaled antibiotics during pulmonary exacerbations is uncertain. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Managing the chronically prescribed antibiotics'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiviral agents</strong> – Antiviral treatment is indicated for people with CF with known or suspected influenza because they are at high risk for severe or complicated disease. Indications and regimens are discussed separately. (See  <a class="medical medical_review" href="/d/html/5985.html" rel="external">"Seasonal influenza in children: Management", section on 'Antiviral therapy'</a> and  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other medications</strong> – We use bronchodilators as pretreatment for airway clearance therapies and to treat asthma-like symptoms. We use glucocorticoids only for the small subset of patients with asthma-like symptoms, although practice varies. (See <a class="local">'Bronchodilators'</a> above and <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory support</strong> – People with respiratory failure or complications (hemoptysis, pneumothorax) are candidates for respiratory support during a pulmonary exacerbation, including supplemental oxygen, noninvasive ventilation, invasive ventilation, or extracorporeal membrane oxygenation support (ECMO). (See <a class="local">'Respiratory support'</a> above.)</p><p></p><p class="bulletIndent1">An episode of respiratory failure should prompt discussion of end-of-life care, quality of life, and possible indications for lung transplantation. Advanced CF lung disease is not a contraindication to intensive care unit (ICU) admission or mechanical ventilation, regardless of the patient's lung transplant status. (See <a class="local">'Intensive care unit treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Following a pulmonary exacerbation, the recovery of lost forced expiratory volume in one second (FEV<sub>1</sub>) is often incomplete. Pulmonary exacerbations are associated with accelerated loss of lung function, decreased quality of life, and increased mortality. Thus, reducing the frequency and optimizing treatment of exacerbations is an important goal of CF care. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059.</a></li><li><a class="nounderline abstract_t">Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet 2021; 397:2195.</a></li><li class="breakAll">Cystic Fibrosis Foundation. 2022 Cystic Fibrosis Foundation Patient Registry Highlights. 2023. Available at: https://www.cff.org/media/29691/download (Accessed on October 30, 2023).</li><li><a class="nounderline abstract_t">Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166:1550.</a></li><li><a class="nounderline abstract_t">Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153:345.</a></li><li><a class="nounderline abstract_t">Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121:64.</a></li><li><a class="nounderline abstract_t">Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134.</a></li><li><a class="nounderline abstract_t">Caverly LJ, VanDevanter DR. The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation. J Pediatric Infect Dis Soc 2022; 11:S40.</a></li><li><a class="nounderline abstract_t">Wagener JS, Rasouliyan L, VanDevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2013; 48:666.</a></li><li><a class="nounderline abstract_t">West NE, Beckett VV, Jain R, et al. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros 2017; 16:600.</a></li><li><a class="nounderline abstract_t">Cogen JD, Oron AP, Gibson RL, et al. Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011; 46:870.</a></li><li><a class="nounderline abstract_t">Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180:802.</a></li><li class="breakAll">Cystic Fibrosis Trust. Standards for the Clinical Care of Children and Adults with cystic fibrosis in the UK. 2nd ed. 2011. Available at: https://www.cysticfibrosis.org.uk/sites/default/files/2022-10/Standards%20of%20care_interim%202022.pdf (Accessed on January 16, 2023).</li><li><a class="nounderline abstract_t">Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13 Suppl 1:S23.</a></li><li class="breakAll">Cystic Fibrosis: Diagnosis and management, National Guideline Alliance (UK). (Ed), National Institute for Health and Care Excellence (NICE), London 2017.</li><li><a class="nounderline abstract_t">Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46:393.</a></li><li><a class="nounderline abstract_t">Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012; 40:61.</a></li><li><a class="nounderline abstract_t">Wagener JS, Williams MJ, Millar SJ, et al. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. J Cyst Fibros 2018; 17:496.</a></li><li><a class="nounderline abstract_t">VanDevanter DR, Hamblett NM, Simon N, et al. Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. J Cyst Fibros 2021; 20:39.</a></li><li><a class="nounderline abstract_t">Goss CH, Heltshe SL, West NE, et al. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med 2021; 204:1295.</a></li><li><a class="nounderline abstract_t">Carter SC, Franciosi AN, O'Shea KM, et al. Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis. Ann Am Thorac Soc 2022; 19:1818.</a></li><li><a class="nounderline abstract_t">Dong K, Huh SM, Lam GY, et al. Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis. J Cyst Fibros 2023; 22:306.</a></li><li><a class="nounderline abstract_t">Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011; 10 Suppl 2:S79.</a></li><li><a class="nounderline abstract_t">Bouzek DC, Ren CL, Thompson M, et al. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis. Pediatr Pulmonol 2022; 57:1709.</a></li><li><a class="nounderline abstract_t">Lechtzin N, Mayer-Hamblett N, West NE, et al. Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. Am J Respir Crit Care Med 2017; 196:1144.</a></li><li><a class="nounderline abstract_t">Schechter MS, Schmidt HJ, Williams R, et al. Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis. J Cyst Fibros 2018; 17:769.</a></li><li><a class="nounderline abstract_t">Anstead M, Saiman L, Mayer-Hamblett N, et al. Pulmonary exacerbations in CF patients with early lung disease. J Cyst Fibros 2014; 13:74.</a></li><li><a class="nounderline abstract_t">Stanojevic S, McDonald A, Waters V, et al. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax 2017; 72:327.</a></li><li><a class="nounderline abstract_t">Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007; 62:360.</a></li><li><a class="nounderline abstract_t">Patel S, Thompson MD, Slaven JE, et al. Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic. Pediatr Pulmonol 2021; 56:1271.</a></li><li><a class="nounderline abstract_t">VanDevanter DR, Morris NJ, Konstan MW. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2016; 15:372.</a></li><li><a class="nounderline abstract_t">Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest 2014; 146:142.</a></li><li><a class="nounderline abstract_t">Schechter MS, Ostrenga JS, Fink AK, et al. Decreased survival in cystic fibrosis patients with a positive screen for depression. J Cyst Fibros 2021; 20:120.</a></li><li><a class="nounderline abstract_t">Asner S, Waters V, Solomon M, et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 2012; 11:433.</a></li><li><a class="nounderline abstract_t">Gonzalez-Rosales N, Kasi AS, McCracken CE, et al. Impact of viral respiratory infections on pulmonary exacerbations in children with cystic fibrosis. Pediatr Pulmonol 2023; 58:871.</a></li><li><a class="nounderline abstract_t">Goffard A, Lambert V, Salleron J, et al. Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients. J Clin Virol 2014; 60:147.</a></li><li><a class="nounderline abstract_t">Etherington C, Naseer R, Conway SP, et al. The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. J Cyst Fibros 2014; 13:49.</a></li><li><a class="nounderline abstract_t">Chin M, De Zoysa M, Slinger R, et al. Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations. J Cyst Fibros 2015; 14:482.</a></li><li><a class="nounderline abstract_t">Muhlebach MS, Hatch JE, Einarsson GG, et al. Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study. Eur Respir J 2018; 52.</a></li><li><a class="nounderline abstract_t">Carmody LA, Caverly LJ, Foster BK, et al. Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. PLoS One 2018; 13:e0194060.</a></li><li><a class="nounderline abstract_t">Castner LM, Zimbric M, Cahalan S, et al. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria. J Cyst Fibros 2021; 20:926.</a></li><li><a class="nounderline abstract_t">Huang YJ, LiPuma JJ. The Microbiome in Cystic Fibrosis. Clin Chest Med 2016; 37:59.</a></li><li><a class="nounderline abstract_t">Hurley MN, Prayle AP, Flume P. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst Rev 2015; :CD009730.</a></li><li><a class="nounderline abstract_t">Shoki AH, Mayer-Hamblett N, Wilcox PG, et al. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013; 144:1659.</a></li><li><a class="nounderline abstract_t">Ratjen F, Waters V, Klingel M, et al. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 2016; 47:829.</a></li><li><a class="nounderline abstract_t">Ordoñez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:1471.</a></li><li><a class="nounderline abstract_t">Esther CR Jr, Muhlebach MS, Ehre C, et al. Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis. Sci Transl Med 2019; 11.</a></li><li><a class="nounderline abstract_t">Sanders DB, Khan U, Heltshe SL, et al. Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation. J Cyst Fibros 2022; 21:574.</a></li><li><a class="nounderline abstract_t">Schechter MS, VanDevanter DR, Pasta DJ, et al. Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Ann Am Thorac Soc 2018; 15:225.</a></li><li><a class="nounderline abstract_t">Balaguer A, González de Dios J. Home versus hospital intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2015; :CD001917.</a></li><li><a class="nounderline abstract_t">Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997; 10:896.</a></li><li><a class="nounderline abstract_t">Collaco JM, Green DM, Cutting GR, et al. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010; 182:1137.</a></li><li><a class="nounderline abstract_t">Davis PB, di Sant'Agnese PA. Assisted ventilation for patients with cystic fibrosis. JAMA 1978; 239:1851.</a></li><li><a class="nounderline abstract_t">Smith MA, McGarry ME, Ly NP, Zinter MS. Outcomes of Children With Cystic Fibrosis Admitted to PICUs. Pediatr Crit Care Med 2020; 21:e879.</a></li><li><a class="nounderline abstract_t">Oud L. Critical illness among adults with cystic fibrosis in Texas, 2004-2013: Patterns of ICU utilization, characteristics, and outcomes. PLoS One 2017; 12:e0186770.</a></li><li><a class="nounderline abstract_t">Kapnadak SG, Dimango E, Hadjiliadis D, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros 2020; 19:344.</a></li><li><a class="nounderline abstract_t">Pollak M, Shaw M, Wilson D, et al. Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations. Pediatr Pulmonol 2021; 56:2036.</a></li><li><a class="nounderline abstract_t">Hordvik NL, Sammut PH, Judy CG, et al. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 154:156.</a></li><li><a class="nounderline abstract_t">Hester KL, Powell T, Downey DG, et al. Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: a UK Survey. J Cyst Fibros 2007; 6:311.</a></li><li><a class="nounderline abstract_t">Dovey M, Aitken ML, Emerson J, et al. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007; 132:1212.</a></li><li><a class="nounderline abstract_t">Muirhead CA, Lanocha N, Markwardt S, MacDonald KD. Evaluation of rescue oral glucocorticoid therapy during inpatient cystic fibrosis exacerbations. Pediatr Pulmonol 2021; 56:891.</a></li><li><a class="nounderline abstract_t">Davis CS, Faino AV, Onchiri F, et al. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Ann Am Thorac Soc 2023; 20:75.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. 2022. Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on January 09, 2023).</li><li><a class="nounderline abstract_t">Hong E, Almond LM, Chung PS, et al. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Clin Pharmacol Ther 2022; 111:1324.</a></li><li><a class="nounderline abstract_t">Dwyer TJ, Robbins L, Kelly P, et al. Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial. J Physiother 2015; 61:142.</a></li><li><a class="nounderline abstract_t">Schechter MA, Ganapathi AM, Englum BR, et al. Spontaneously Breathing Extracorporeal Membrane Oxygenation Support Provides the Optimal Bridge to Lung Transplantation. Transplantation 2016; 100:2699.</a></li><li><a class="nounderline abstract_t">Biscotti M, Gannon WD, Agerstrand C, et al. Awake Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation: A 9-Year Experience. Ann Thorac Surg 2017; 104:412.</a></li><li><a class="nounderline abstract_t">Heltshe SL, Goss CH, Thompson V, et al. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax 2016; 71:223.</a></li><li><a class="nounderline abstract_t">Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182:627.</a></li><li><a class="nounderline abstract_t">Gold LS, Patrick DL, Hansen RN, et al. Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). J Cyst Fibros 2019; 18:886.</a></li><li><a class="nounderline abstract_t">Sequeiros IM, Jarad NA. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis 2012; 9:213.</a></li></ol></div><div id="topicVersionRevision">Topic 110933 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2772657" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Identification of the cystic fibrosis gene: chromosome walking and jumping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34090606" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34090606" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406843" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207152" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Predictive 5-year survivorship model of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796433" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17643762" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36069900" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22888106" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457954" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28126911" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21465675" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729669" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729669" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24856775" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : European Cystic Fibrosis Society Standards of Care: Best Practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24856775" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : European Cystic Fibrosis Society Standards of Care: Best Practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20967845" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22135280" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29685810" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682670" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34469706" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35713619" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36572614" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658647" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35429154" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28608719" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30017327" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24029220" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pulmonary exacerbations in CF patients with early lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27539619" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17387214" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33434352" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603642" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480974" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pulmonary medication adherence and health-care use in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32800486" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Decreased survival in cystic fibrosis patients with a positive screen for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22579414" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36479634" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Impact of viral respiratory infections on pulmonary exacerbations in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24637203" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891398" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25544473" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946004" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522532" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33612403" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26857768" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The Microbiome in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226131" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23868694" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26585432" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969869" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944166" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34857494" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29140726" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671062" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Home versus hospital intravenous antibiotic therapy for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9150331" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20581166" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/642113" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Assisted ventilation for patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304511" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcomes of Children With Cystic Fibrosis Admitted to PICUs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29065161" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Critical illness among adults with cystic fibrosis in Texas, 2004-2013: Patterns of ICU utilization, characteristics, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32115388" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33830642" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8680672" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291836" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: a UK Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646219" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33289316" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Evaluation of rescue oral glucocorticoid therapy during inpatient cystic fibrosis exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36044723" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36044723" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35292968" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096013" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26910331" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Spontaneously Breathing Extracorporeal Membrane Oxygenation Support Provides the Optimal Bridge to Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28242078" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Awake Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation: A 9-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25911223" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463179" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31126901" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22637747" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
